Enzychem Lifesciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Ki-Young Sohn
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 5.1% |
| Management average tenure | no data |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
Positive Sentiment Still Eludes Enzychem Lifesciences Corporation (KOSDAQ:183490) Following 25% Share Price Slump
Dec 09
Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 13There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price
Aug 13Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt
May 09If You Had Bought Enzychem Lifesciences (KOSDAQ:183490) Shares A Year Ago You'd Have Earned 43% Returns
Feb 17
CEO
Ki-Young Sohn
no data
Tenure
Ki-Young Sohn serves as the Chairman and Chief Executive Officer at Enzychem Lifesciences Corporation. Ki-Young Sohn holds MBA from graduate School of Business, Dept. of Business Administration Korea Unive...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Executive Officer | no data | no data | 5.1% ₩ 6.0b | |
| Member of Corporate Advisory Committee & CTO | 3.1yrs | no data | no data | |
| Chief Scientific Officer & Member of the Board of Directors | no data | no data | no data | |
| CMO & Director | 7.9yrs | no data | no data | |
| Executive Director | no data | no data | no data | |
| VP & Executive Director | no data | no data | no data | |
| Director | 7.9yrs | no data | no data | |
| Vice Chairman | no data | no data | 0.080% ₩ 93.7m | |
| Director | 7.9yrs | no data | no data | |
| Director | 7.9yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data |
7.9yrs
Average Tenure
71yo
Average Age
Experienced Board: A183490's board of directors are considered experienced (7.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/05 16:46 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enzychem Lifesciences Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Sang-Hun Lee | iM Securities |